PHASE II STUDY OF THE SAFETY AND SURROGATE MARKER EFFICACY OF BUTYLDEOXYNOJIRIMYCIN (SC-48334) AND AZT IN SYMPTOMATIC HIV-1 INFECTED PATIENTS WITH 200 - 500 CD4+ CELLS/MM3. (NOTE: ASYMPTOMATIC HIV-1 INFECTED PATIENTS ALSO ELIGIBLE):